sotorasib
Sponsor Amgen INC · listed as AMGN
sotorasib is a drug asset sponsored by Amgen INC, listed as AMGN. CSA tracks 1 forward catalyst for it — the nearest is a readout expected Jun 30, 2027 (day precision, medium confidence), tied to trial NCT05920356. That trial is in Phase 3 and currently recruiting, studying Non-Small Cell Lung Cancer (NSCLC). It appears across 3 tracked trials in the CSA sample.
Next catalyst
Trial & sponsor
Trials for sotorasib in the CSA sample
| Trial | Phase | Status | Primary completion | Role | Lead sponsor | Condition(s) |
|---|---|---|---|---|---|---|
| NCT06497556 | Phase 3 | Active, not recruiting | 2026-05-19 | Active comparator | Hoffmann-La Roche | Non-Small Cell Lung Cancer; KRAS G12C Lung Cancer |
| NCT05920356 catalyst | Phase 3 | Recruiting | 2027-06-30 | Experimental | Amgen | Non-Small Cell Lung Cancer (NSCLC) |
| NCT06252649 | Phase 3 | Recruiting | 2028-09-25 | Experimental | Amgen | Metastatic Colorectal Cancer |
Each trial links to its ClinicalTrials.gov record; primary completion dates are as registered there.
Data, not investment advice. CSA is information, not a recommendation to buy, sell or hold any security. Estimated catalyst dates routinely slip and are graded by confidence — verify against the source link before acting.
This page is one record from the free CSA sample. The full snapshot covers active, industry-sponsored Phase 3 trials in cardiometabolic, oncology and immunology. Every forward catalyst carries its date, confidence grade and source link, and is linked to its sponsor's ticker when the sponsor is a listed company.
Get the full dataset — $499 → More AMGN catalysts